For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
NAD+ (nicotinamide adenine dinucleotide) is the coenzyme at the center of cellular energy metabolism, DNA repair, and sirtuin-mediated aging regulation. NAD+ levels decline approximately 50% between ages 40 and 60 through multiple mechanisms including increased CD38-mediated degradation and reduced NAMPT-driven synthesis. Two oral precursors -- NMN and NR -- have the most robust human clinical evidence: NMN published in Science (Yoshino et al. 2021, n=25) showed increased muscle insulin sensitivity; NR published in Nature Communications (McDermott et al. 2024, NICE trial, n=90) improved 6-minute walk distance in peripheral artery disease by 17.6 meters vs. placebo. The human evidence base is genuinely positive but limited: trials are short (10 to 12 weeks), small (n=20 to 90), and have produced inconsistent results on functional endpoints. Injectable NAD+ (IV and subcutaneous) is widely used in wellness settings despite a fundamental scientific dispute over whether the NAD+ molecule -- too large and charged to enter cells directly -- actually delivers benefit via the proposed cellular mechanism.
NAD+ requires an unusual framing note for this research series: it is a coenzyme, not a peptide. Its inclusion here is justified on three grounds: (1) NAD+ precursors NMN and NR are routinely co-sold by peptide research chemical vendors as part of longevity stacks alongside peptides like SS-31, MOTS-c, and Epithalon; (2) the underlying biology is directly mechanistically complementary to mitochondrial peptides covered elsewhere in this series (SS-31 stabilizes mitochondrial membrane architecture; NAD+ replenishes the electron transfer cofactors that operate within that structure); and (3) the human evidence base for NAD+ precursors is more robust than most compounds in this series and requires honest coverage for readers making purchasing decisions.
The most important fact about delivery routes -- and the question most relevant to readers considering the subcutaneous NAD+ sold by peptide vendors -- is this: NAD+ is a large (MW 663 Da), highly charged molecule that experts believe cannot enter cells intact. Eric Verdin, President of the Buck Institute for Research on Aging, stated directly: "NAD+ is too big to enter cells and is mostly broken down into nicotinamide when injected. Oral precursors like NMN or NR are a better bet for most people." A 2024 randomized pilot study (ChromaDex, medRxiv preprint) compared IV NAD+ vs. IV NR vs. oral NR: IV NR raised NAD+ by 20.7% in 3 hours and outperformed IV NAD+ on this metric; IV NAD+ produced white blood cell and neutrophil increases suggesting a potential inflammatory response at supraphysiological extracellular NAD+ concentrations. If injected NAD+ is largely converted to nicotinamide before cellular uptake, subcutaneous NAD+ injection may functionally deliver nicotinamide rather than NAD+ -- a far less expensive vitamin B3 derivative that does not share NAD+'s mechanism.
The cancer question requires specific attention. A mouse study (Maric et al.) found that NR supplementation appeared to increase brain metastasis rate in a model of aggressive triple-negative breast cancer -- a result widely mischaracterized in popular media as "NR causes cancer." The same molecule has shown protective effects in other tumor models. Current scientific consensus: no clinical evidence that NAD+ precursors cause cancer in healthy individuals; the theoretical concern that elevated NAD+ could fuel energy-hungry cancer cells remains under study; individuals with active cancer or history of cancer should exercise caution and consult oncologists. The NIA Interventions Testing Program (the most rigorous lifespan extension testing program in the US) found that NR supplementation did not extend lifespan in mice -- an important negative result for the longevity narrative.
NAD+ was first identified in 1906 by Harden and Young as a factor required for fermentation. Its role as a fundamental coenzyme in oxidation-reduction reactions was established through decades of biochemical research. It was not until the 2000s that its role as a substrate for non-redox enzymes -- particularly sirtuins and PARPs -- was recognized, reframing NAD+ from a metabolic cofactor to a master regulator of aging-relevant cellular processes.
The clinical interest in NAD+ supplementation was catalyzed by several converging discoveries: Guarente's identification that sirtuins (SIRT1-7) require NAD+ as a substrate for their deacetylase activity; the demonstration that calorie restriction (one of the most reproducible lifespan-extending interventions) raises NAD+ levels; and multiple preclinical studies showing that NAD+ supplementation mimics aspects of calorie restriction in animals.
The most important mechanistic finding linking NAD+ to aging: Camacho-Pereira et al. (Cell Metabolism, 2016) established that CD38 (an NADase enzyme) increases 2 to 3-fold in tissues during aging in both mice and humans (confirmed in human adipose tissue from young vs. old subjects). CD38 is the primary driver of age-related NAD+ decline. The other major drivers are: increased DNA damage activating PARP (a major NAD+ consumer); decreased NAMPT expression reducing salvage pathway NAD+ synthesis. These three mechanisms -- excess CD38, activated PARP, reduced NAMPT -- collectively explain why whole blood and tissue NAD+ levels fall approximately 50% between ages 40 and 60.
The commercial ecosystem around NAD+ is substantial. NR (branded as NIAGEN, ChromaDex) had US sales exceeding $60 million in 2022 alone. NMN has a competitive market despite its unsettled FDA status. IV NAD+ infusion therapy is available at thousands of wellness clinics globally. Subcutaneous NAD+ injection is sold by peptide research chemical vendors alongside compounds like BPC-157, TB-500, and SS-31. This commercial scale substantially outpaces the clinical evidence base.
NAD+ functions as both an electron carrier (redox reactions) and a substrate for non-redox enzymes. The two functions are mechanistically separate and serve different biological roles.
Redox function: NAD+ accepts electrons from metabolic substrates (glucose, fatty acids, amino acids) to become NADH, which then donates electrons to Complex I of the mitochondrial electron transport chain, driving ATP synthesis. This is the classical bioenergetics role of NAD+. NADH/NAD+ ratio regulation determines the rate of glycolysis, the TCA cycle, and oxidative phosphorylation. Declining NAD+ with age impairs this electron shuttling, reducing mitochondrial energy production efficiency.
Sirtuin activation: SIRT1 through SIRT7 are NAD+-dependent deacetylases that regulate hundreds of downstream targets. Key effects: SIRT1 activates PGC-1alpha (driving mitochondrial biogenesis), suppresses NF-kB (reducing inflammation), and deacetylates p53 (affecting apoptosis). SIRT3 (mitochondrial sirtuin) activates the TCA cycle and oxidative phosphorylation enzymes by deacetylation. SIRT6 regulates genomic stability and DNA repair. All sirtuins are enzymatically inactive without NAD+; their activity declines proportionally with NAD+ availability during aging.
PARP activation: PARP1 and PARP2 detect DNA strand breaks and consume NAD+ massively (up to 100 molecules per activation event) to generate poly-ADP-ribose chains that signal DNA repair machinery. Chronic DNA damage during aging over-activates PARPs, depleting cellular NAD+ and competing with sirtuins for the same pool. PARP inhibition (or adequate NAD+ supply) allows sirtuin activity to be maintained despite ongoing DNA damage.
CD38/cADPR pathway: CD38 (a transmembrane glycoprotein and NADase) cleaves NAD+ to produce cyclic ADP-ribose (cADPR), which mobilizes calcium and activates immune and inflammatory signaling. CD38 dramatically increases with aging and senescence-associated inflammation (inflammaging), becoming the dominant driver of NAD+ depletion. This creates a feed-forward loop: more inflammation produces more CD38, which depletes more NAD+, which reduces sirtuin activity, which allows more inflammation.
Precursor pathway distinction: NR enters cells via equilibrative nucleoside transporters (ENTs) and is phosphorylated by NRK1/2 enzymes to become NMN, then adenylated by NMNAT enzymes to become NAD+. NMN has an additional phosphate group making it larger; it may be dephosphorylated to NR by CD73 extracellularly before cell entry, or enter directly via the SLC12A8 transporter identified in 2019 (though this transporter's expression in humans is tissue-specific and debated). Both NR and NMN therefore ultimately generate NAD+ through the same salvage pathway, though via slightly different entry routes.
Yoshino 2021 (Science): NMN increased insulin-stimulated glucose disposal by approximately 25% (measured by hyperinsulinemic-euglycemic clamp -- the gold standard for insulin sensitivity measurement). Phosphorylation of AKT at Ser473 and Thr308 increased in skeletal muscle biopsies, confirming tissue-level insulin signaling improvement. Expression of platelet-derived growth factor receptor beta (PDGFR-beta) and other muscle remodeling genes was upregulated. Critically: muscle NAD+ content itself did not significantly increase, but NMN metabolites (MeNAM, Me2PY, Me4PY) increased, suggesting greater NAD+ turnover rather than NAD+ accumulation. Body composition, blood pressure, plasma glucose, lipids, and muscle strength and fatigability did not change significantly.
This is the most important human functional outcome study for NMN: published in Science, using gold-standard insulin sensitivity measurement (hyperinsulinemic-euglycemic clamp), demonstrating a tissue-level metabolic effect beyond simply raising blood NAD+ markers.
Important caveat: n=25 (13 NMN, 12 placebo) in a specific population (postmenopausal overweight/obese prediabetic women). Whether the insulin sensitivity benefit generalizes to men, younger adults, or healthy individuals without metabolic dysfunction is unknown.
Igarashi 2022 (npj Aging): NMN 250 mg/day in healthy older men (n=42, 12 weeks) increased whole blood NAD+ sixfold, improved gait speed and grip strength in some analyses, but did not change skeletal muscle mass, fat mass, lipids, insulin sensitivity, glucose tolerance, or endothelial function. Functional benefit was selective and modest.
Liao 2021: NMN 300 to 600 mg/day in recreational runners improved aerobic capacity measures but this study has been criticized for poor blinding methodology.
The Yoshino 2021 Science paper is the most credible single functional endpoint result for NMN in humans. A 25% increase in muscle insulin sensitivity measured by hyperinsulinemic-euglycemic clamp in prediabetic women is clinically meaningful if it replicates. The mechanistic finding -- that muscle NAD+ turnover (not accumulation) mediates the effect -- is an important nuance. The limitation is n=25 in a specific population, 10 weeks duration. Larger trials in broader populations are needed to confirm this signal. The Igarashi older men data provides modest corroboration for functional improvement (gait speed) but not metabolic effects.
NICE trial (McDermott 2024, n=90, 6 months): Between-group difference for NR vs. placebo: +17.6 meters on 6-minute walk distance (90% CI: +1.8 to infinity). Among participants with at least 75% pill adherence, NR improved 6MWD by 31.0 meters vs. placebo -- a clinically meaningful improvement. Resveratrol added no benefit to NR alone. Treadmill walking time also improved with NR.
The 17.6 meter improvement on 6MWT is at the lower boundary of what is considered clinically meaningful in PAD (typically 20 to 30 meters or more). The directional consistency between overall and per-protocol analyses supports a real effect. The one-sided 90% CI was used because PAD trials typically test one directional hypothesis (improvement). Standard two-sided p-value was borderline, making this a signal-generating positive trial rather than definitive efficacy evidence.
Martens 2018 (n=30, crossover): NR raised whole blood NAD+ metabolites. Cardiovascular signal: NR lowered systolic blood pressure by 3.9 mmHg and pulse wave velocity (arterial stiffness measure) trended toward improvement in the middle-aged and older adult subgroup. Modest signals consistent with vascular benefit.
Meta-analysis context: A 2024 meta-analysis (PMC, 8 NMN RCTs, n=342, glucose/lipid outcomes) found no significant effect of NMN on fasting glucose, insulin, HbA1c, HOMA-IR, or lipid profiles -- underscoring that beneficial signals in specific functional endpoints do not automatically generalize to metabolic biomarkers.
The NICE trial is the most important published RCT for NR in a disease population with functional endpoints. A 17.6 meter improvement on 6MWT in PAD patients is directionally positive and consistent with NR supporting mitochondrial function in a condition characterized by ischemic mitochondrial energy deficit. However, the trial used a one-sided 90% CI analysis reflecting pre-specified directional hypothesis testing, and the effect size sits at the lower boundary of clinical meaningfulness. This is appropriately characterized as a strong positive signal warranting confirmatory trials rather than demonstrated efficacy.
The ChromaDex 2024 pilot study directly compared delivery routes. Key findings: IV NR outperformed IV NAD+ on NAD+ elevation: IV NR raised blood NAD+ by 20.7% at 3 hours, significantly outperforming IV NAD+ on this endpoint (p less than 0.01) and oral NR (p less than 0.01) acutely. IV NR infusion time was 75% shorter than IV NAD+. IV NAD+ produced increases in white blood cell and neutrophil counts suggesting a potential inflammatory response -- IV NR did not. No serious adverse events in any arm through 14-day follow-up.
The scientific basis for why injected NAD+ may underperform injected NR: NAD+ (MW 663 Da, highly negatively charged at physiological pH) faces significant barriers to cellular membrane crossing. The standard membrane transport pathways used by small molecule nutrients are not available to NAD+. Most injected NAD+ in systemic circulation is degraded by CD38 and other ectonucleotidases to produce nicotinamide, which IS small enough to enter cells and be salvaged back to NAD+ via the NAMPT pathway. But if the benefit derives from nicotinamide rather than NAD+, subcutaneous NAD+ injection is functionally delivering an expensive form of vitamin B3.
Subcutaneous NAD+ injections (as sold by peptide vendors): There is no published controlled trial specifically evaluating subcutaneous NAD+ injection. Community protocols describe 50 to 200 mg subcutaneous injection 2 to 3 times weekly. The injection site burning/stinging reported almost universally by users is consistent with the local tissue response to a highly charged molecule. Whether the benefit profile (if any) is mediated by NAD+ reaching cells intact, by local nicotinamide generation, or by the GPR109A receptor activation from nicotinamide (which can cause vasodilation) is entirely unstudied.
IV NAD+ for addiction treatment: The longest clinical history of injectable NAD+ is in addiction medicine. IV NAD+ has been used for alcohol and drug withdrawal management since at least 1961. This clinical use predates controlled trial evidence and is based on clinical observation, not RCT data. Case series and retrospective reports suggest benefit for withdrawal symptoms and cravings. No adequately powered controlled trial has established efficacy for addiction treatment by current standards.
For practical comparison across five delivery routes: Subcutaneous NAD+ (peptide vendor): No controlled human trial. May primarily deliver nicotinamide. Burns on injection. Requires cold chain. Evidence grade: anecdotal. IV NAD+: 100% bioavailability in blood but potentially minimal cellular uptake of intact NAD+. Infusion adverse effects (nausea, cramping, chest tightness) require slow rate. Produces inflammatory signal in 2024 pilot. Clinical use primarily addiction medicine, uncontrolled. Evidence grade: weak observational. IV NR: Superior to IV NAD+ on acute blood NAD+ elevation in 2024 pilot. Better tolerated. No published controlled trial for clinical endpoints. Evidence grade: single pilot study. Oral NR (NIAGEN): Most clinical trial evidence. Multiple RCTs including NICE trial (n=90). GRAS. No injection required. Evidence grade: Tier 2 with specific populations. Oral NMN: Growing RCT evidence including Science publication (Yoshino 2021). Regulatory status unsettled in US but widely available. Evidence grade: Tier 2 with specific populations.
The delivery route question is the most practically important topic for readers of this series considering subcutaneous NAD+ from peptide vendors. The scientific evidence strongly favors oral NR or NMN over injectable NAD+ for several reasons: oral precursors have controlled trial evidence for functional endpoints; injectable NAD+ may not deliver intact NAD+ to cells; IV NAD+ produces an inflammatory signal not seen with IV NR; and the cellular uptake barriers to injected NAD+ are well-characterized by leading NAD+ researchers. Subcutaneous NAD+ injection, as sold by peptide vendors, has no published controlled trial data and may primarily deliver nicotinamide -- at substantially higher cost than oral supplementation.
NR-SAFE Parkinson's (Brakedal 2022, Cell Metabolism, n=30): NR 1,000 mg/day was safe. NAD+ metabolome significantly elevated in blood. No significant improvement in MDS-UPDRS clinical severity score over 12 weeks. Phase 2 trial (NRPD, NCT03816020) is underway with longer duration and larger n.
NR-SAFE high-dose (Berven 2023, Nature Communications, n=20): NR 3,000 mg/day for 4 weeks was safe, with 3.7-fold increase in whole blood NAD+. No significant improvement in clinical Parkinson's outcomes over 4 weeks. This was a safety/dose-finding study, not powered for efficacy.
Vreones 2022 (Aging Cell, n=22): Oral NR raised NAD+ in plasma extracellular vesicles enriched for neuronal origin, and reduced neurofilament light chain (NFL) -- a biomarker of neurodegeneration -- in these vesicles. This suggests NR-derived NAD+ does reach the brain compartment. The NFL finding is hypothesis-generating but not a clinical endpoint.
Long-COVID NR trial (Arnold 2024/2025, n=61, 24 weeks): NR 2,000 mg/day did not significantly improve the primary cognitive outcomes (ECog, RBANS) in long-COVID patients. NAD+ levels were not formally reported as significantly elevated by the primary analysis. A 51% dropout rate by 20 weeks significantly reduced trial power.
The pattern across neurodegeneration applications: NAD+ can be raised in blood and (as suggested by Vreones) may reach brain-relevant compartments. Clinical cognitive or neuroprotective benefit has not been demonstrated in any adequately powered RCT. All trials to date are safety or pilot studies with insufficient power for efficacy conclusions.
The neurodegenerative application for NAD+ precursors has compelling mechanistic rationale (SIRT3, PARP-1, mitochondrial function all decline in aging brain; NAD+ depletion is documented in neurodegeneration) and early biomarker signals (NFL reduction in neuronal-origin extracellular vesicles with NR). But no controlled trial has yet demonstrated clinical cognitive benefit. The Parkinson's Phase 2 trial (NRPD) and likely future Alzheimer's trials will be more informative. Current status: mechanistically promising, clinically unproven for cognitive endpoints.
Martens 2018 (NR, n=30): NR lowered systolic blood pressure by 3.9 mmHg and showed a trend toward reduced pulse wave velocity in the middle-aged and older adult subgroup. No significant changes in diastolic blood pressure or other cardiovascular parameters at the group level. Total and LDL cholesterol numerically lower with NR but not statistically significant.
MIB-626 high-dose NMN (n=30, 2,000 mg/day, 28 days): Significant reductions in total cholesterol, LDL, and non-HDL cholesterol. Body weight decreased. Diastolic blood pressure decreased. Blood NAD+ substantially elevated. This is the highest NMN dose tested in humans to date and shows lipid effects not consistently seen at lower doses.
Meta-analysis (Zheng 2024, 8 NMN RCTs, n=342): No significant benefit of NMN supplementation on fasting glucose, fasting insulin, HbA1c, HOMA-IR, total cholesterol, LDL, HDL, or triglycerides in random-effects meta-analysis. Note: this meta-analysis covers primarily lower-dose studies and healthy/non-diabetic populations where ceiling effects may apply.
Akasaka 2023 (NMN in older T2D patients): NMN 250 mg/day improved gait speed by 0.2 m/s more than placebo over 3 months in older diabetic patients with impaired physical performance. The improvement is clinically meaningful (0.1 m/s is often cited as a meaningful threshold). Blood glucose parameters improved modestly.
The overall picture on metabolic and cardiovascular biomarkers: dose appears to matter substantially (2,000 mg/day MIB-626 effects not replicated at 250 to 500 mg/day in most studies); population matters (effects most consistent in patients with metabolic dysfunction -- prediabetes, PAD -- not in healthy populations); and blood NAD+ elevation does not automatically predict clinical benefit.
The metabolic and cardiovascular biomarker data for NAD+ precursors is genuinely inconsistent. Individual trials show positive signals (blood pressure and arterial stiffness with NR; lipid improvements with high-dose NMN; gait speed in older diabetic patients) that meta-analyses across all populations fail to confirm as consistent effects. This pattern suggests that: NAD+ precursors may benefit individuals with demonstrable metabolic dysfunction or NAD+ deficiency more than healthy individuals with adequate baseline NAD+; dose-response exists and lower doses in healthy populations may show minimal effect; and individual variability in baseline NAD+ levels and response is high, limiting population-level effect sizes.
Administered via IV infusion in clinical settings.
For readers of this series considering injectable NAD+ from peptide vendors: the scientific case for subcutaneous NAD+ rests on the assumption that the molecule enters cells intact. This assumption is disputed by leading NAD+ researchers including Eric Verdin (Buck Institute). The 2024 pilot data showing IV NR outperforms IV NAD+ on blood NAD+ elevation, combined with IV NAD+ producing an inflammatory signal, supports the concern that extracellular NAD+ at supraphysiological concentrations does not efficiently translate to intracellular NAD+ replenishment. Oral NMN or NR at 250 to 1,000 mg/day, from a verified manufacturer (GRAS-certified NR from ChromaDex/Niagen Bioscience; pharmaceutical-grade NMN with certificate of analysis), is the evidence-supported approach. Product quality matters substantially -- an analysis of 22 NMN brands found most failed to meet label claims in independent testing. Third-party verification is not optional.
NAD+ vs. SS-31 (mitochondrial comparison): These are complementary, not competing. SS-31 targets the physical structure of the inner mitochondrial membrane by binding cardiolipin and stabilizing cristae. NAD+ replenishes the electron carrier (NADH/NAD+ ratio) that operates within that structure. SS-31 has a narrower, more specific mechanism; NAD+ precursors affect a broader range of NAD+-dependent enzymes (sirtuins, PARPs, CD38) across all tissues. SS-31 has an FDA-approved indication (Barth syndrome) with Phase 2 RCT evidence across multiple conditions; NAD+ precursors have stronger evidence than most research peptides but no approved indication.
NAD+ vs. MOTS-c (AMPK pathway overlap): MOTS-c activates AMPK, which upregulates NAMPT (the enzyme that makes NMN from nicotinamide, the rate-limiting step in NAD+ synthesis). MOTS-c and NAD+ precursors may be mechanistically synergistic -- MOTS-c drives the synthesis arm; NAD+ precursors provide substrate. This is a theoretical synergy without combination human trial data.
NAD+ vs. MK-677 (anti-aging compound comparison): MK-677 and NAD+ precursors are often combined in anti-aging protocols despite operating through entirely different mechanisms (GH axis vs. NAD+ metabolism). MK-677 has a 2-year double-blind RCT (Nass 2008); NAD+ precursors have multiple shorter RCTs. MK-677's insulin resistance liability (consistently documented) conflicts directly with NMN's insulin sensitivity benefit (Yoshino 2021) -- the two compounds may partially oppose each other at the metabolic level.
NMN vs. NR (which precursor): NR has a longer published history, GRAS status, and a larger total published trial count. NMN's best result (Science 2021, muscle insulin sensitivity) is more compelling as a functional endpoint than any single NR functional trial, but NR's NICE trial (n=90) has a larger sample size. Both work through the same salvage pathway. NMN may have modest cellular entry advantages via SLC12A8 transporter in some tissues. For most purposes, either is a reasonable choice at equivalent evidence tiers; product quality and regulatory clarity currently favor NR.
NAD+ precursors have an excellent short-term safety record across dozens of human clinical trials. The main adverse effects are gastrointestinal: nausea, diarrhea, flatulence, particularly at doses above 1,000 mg/day. At very high doses of nicotinamide (a metabolite of all NAD+ precursors), there are theoretical concerns about methyl group depletion (since nicotinamide methylation is the primary excretion pathway) and potential feedback inhibition of SIRT1. High-dose niacin (a different B3 form) causes the well-known flushing reaction via GPR109A receptor; NMN and NR do not cause significant flushing at typical doses.
NR safety profile: GRAS designation for food uses from the FDA. Well-tolerated up to 2,000 mg/day in human trials. NR-SAFE trial (Norway, Nature Communications, 2023): 3,000 mg/day in Parkinson's disease patients was safe with a 3.7-fold increase in whole blood NAD+. No serious adverse events attributable to NR in any published controlled trial.
NMN safety profile: Safe and well-tolerated in Japanese Phase 1 study at 100 to 500 mg single oral doses with no serious adverse events (Irie et al. 2020, Endocrine Journal). Subsequent trials up to 900 mg/day for 60 days and 1,250 mg/day in other studies have not identified serious adverse effects. The regulatory status concern (FDA 2022 IND authorization ruling, reversed 2024) is administrative, not safety-related.
The cancer question (unresolved): A mouse experiment by Maric et al. found that NR supplementation increased brain metastasis rate in an aggressive triple-negative breast cancer model. This has been widely misinterpreted. The study used cancer cells injected subcutaneously, not the mammary fat pad model better reflecting human breast cancer. Other mouse models (Jiang et al.) found NMN reduced tumor growth. The NIA Interventions Testing Program found NR did not extend lifespan in mice. Current consensus: no clinical evidence NR or NMN cause cancer in humans; individuals with active cancer should exercise caution pending longer human studies.
Injectable NAD+ safety: Distinct from oral precursors. IV NAD+ infusions cause nausea, chest tightness, muscle cramping, and require extremely slow infusion rates (2 mg/min over 6 hours for 750 mg). The 2024 ChromaDex pilot study (medRxiv) found IV NAD+ produced white blood cell and neutrophil count increases suggesting inflammation, while IV NR did not. Subcutaneous NAD+ from research chemical vendors has no controlled safety data, though the mechanism-based concern (that extracellular NAD+ at supraphysiological concentrations may trigger immune signaling) applies. Long-term safety of either injectable route has not been systematically studied.
NAD+ precursors (NMN and NR) are among the most evidence-supported compounds in this research series for specific endpoints in specific populations. This is a more honest assessment than the longevity marketing suggests, and also more positive than the dismissive "just hype" response that some experts offer.
What the evidence shows: NMN at 250 mg/day for 10 weeks improved skeletal muscle insulin sensitivity by 25% in prediabetic women, measured by gold-standard hyperinsulinemic-euglycemic clamp, published in Science. NR at 1,000 mg/day for 6 months improved 6-minute walk distance by 17.6 meters in PAD patients, published in Nature Communications. Both are genuinely positive results in specific populations with functional endpoints, not just biomarker changes.
What the evidence does not show: NAD+ precursors have not been shown to extend lifespan in the most rigorous animal testing available (NIA Interventions Testing Program). Benefits in metabolic and cardiovascular biomarkers are inconsistent across trials and populations. The broad anti-aging narrative -- "restore NAD+ to youthful levels and reverse aging" -- runs well ahead of the controlled human evidence, which is limited to specific endpoints in specific populations over short durations (10 to 24 weeks maximum).
The most important practical guidance for readers of this series: If you are considering NAD+ supplementation for longevity or metabolic support, oral NR or NMN is favored by the evidence over injectable NAD+. The injectable NAD+ sold by peptide vendors likely does not deliver intact NAD+ to cells -- it is degraded to nicotinamide in circulation. Leading NAD+ researchers including the President of the Buck Institute have stated this publicly. IV NR outperforms IV NAD+ on acute NAD+ elevation in the only comparative study published. Oral precursors have RCT evidence; subcutaneous NAD+ does not. Oral NR (especially NIAGEN, with GRAS status and the largest human evidence base) or NMN at 250 to 1,000 mg/day represents the evidence-supported approach for this audience.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use